MDMA (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "MDMA" in Chinese language version.

refsWebsite
Global rank Chinese rank
1st place
1st place
2nd place
23rd place
4th place
5th place
5th place
12th place
3rd place
8th place
222nd place
216th place
2,494th place
2,317th place
610th place
388th place
14th place
18th place
low place
low place
399th place
208th place
274th place
320th place
6,166th place
3,264th place
68th place
209th place
7,538th place
low place
731st place
808th place
7th place
31st place
low place
low place
low place
6,142nd place
447th place
581st place
34th place
129th place
4,052nd place
159th place
1,248th place
434th place
918th place
1,784th place
9th place
2nd place

acs.org

pubs.acs.org

archive.today

books.google.com

doi.org

dovepress.com

drugabuse.gov

drugs.com

  • Anderson, Leigh (编). MDMA. Drugs.com. Drugsite Trust. 18 May 2014 [30 March 2016]. (原始内容存档于2016-03-23). 

elsevier.com

linkinghub.elsevier.com

europa.eu

emcdda.europa.eu

fda.gov

  • Research, Center for Drug Evaluation and. Fact Sheet: Breakthrough Therapies. FDA. 2019-02-09 [2022-03-05]. (原始内容存档于2022-04-27) (英语). A breakthrough therapy is a drug:
     · intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition and
     · preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
     

healthnewsreview.org

justice.gov

liebertpub.com

nhtsa.gov

nih.gov

ncbi.nlm.nih.gov

toxnet.nlm.nih.gov

  • 3,4-METHYLENEDIOXYMETHAMPHETAMINE. Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008 [22 August 2014]. (原始内容存档于2019-04-04). /EPIDEMIOLOGY STUDIES/ /Investigators/ compared the prevalence of Diagnostic and Statistical Manual version IV (DSM-IV) mental disorders in 30 current and 29 former ecstasy users, 29 polydrug and 30 drug-naive controls. Groups were approximately matched by age, gender and level of education. The current ecstasy users reported a life-time dose of an average of 821 and the former ecstasy users of 768 ecstasy tablets. Ecstasy users did not significantly differ from controls in the prevalence of mental disorders, except those related to substance use. Substance-induced affective, anxiety and cognitive disorders occurred more frequently among ecstasy users than polydrug controls. The life-time prevalence of ecstasy dependence amounted to 73% in the ecstasy user groups. More than half of the former ecstasy users and nearly half of the current ecstasy users met the criteria of substance-induced cognitive disorders at the time of testing. Logistic regression analyses showed the estimated life-time doses of ecstasy to be predictive of cognitive disorders, both current and life-time. ... Cognitive disorders still present after over 5 months of ecstasy abstinence may well be functional consequences of serotonergic neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA) [Thomasius R et al; Addiction 100(9):1310-9 (2005)] **PEER REVIEWED** PubMed Abstract 

pubmed.ncbi.nlm.nih.gov

nytimes.com

sagepub.com

journals.sagepub.com

springer.com

link.springer.com

thenewslens.com

unodc.org

washingtonpost.com

web.archive.org

wiley.com

onlinelibrary.wiley.com

worldcat.org

youtube.com